MedTrace Logo

The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes

NCT01728467 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-04-02

No results posted yet for this study

Summary

This study builds on data that high-density lipoprotein (HDL) has a number of potentially beneficial effects including directly modulating glucose metabolism through multiple mechanisms. The primary objective of this study is to determine the effects of RVX000222 on postprandial plasma glucose in male individuals with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), during a frequently sampled oral glucose tolerance test (OGTT).

Conditions

Interventions

DRUG

RVX000222

capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days

DRUG

Placebo, RVX000222

capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days

Sponsors & Collaborators

  • Baker Heart and Diabetes Institute

    collaborator OTHER

  • Nucleus Network Ltd

    collaborator OTHER

  • Resverlogix Corp

    lead INDUSTRY

Principal Investigators

  • Professor Bronwyn Kingwell · Baker Heart and Diabetes Institute

  • Dr. Stephen Duffy · Baker Heart and Diabetes Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01728467 on ClinicalTrials.gov